Substituted quinolines as noncovalent proteasome inhibitors
- 1 June 2016
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 24 (11) , 2441-2450
Abstract
No abstract availableKeywords
Funding Information
- National Science Foundation (CHE-1265738)
- National Institutes of Health (CA-142644-01)
This publication has 50 references indexed in Scilit:
- Titanium-Catalyzed Multicomponent Couplings: Efficient One-Pot Syntheses of Nitrogen HeterocyclesAccounts of Chemical Research, 2015
- Regulating the 20S Proteasome Ubiquitin-Independent Degradation PathwayBiomolecules, 2014
- Inhibition of the Human Proteasome by Imidazoline ScaffoldsJournal of Medicinal Chemistry, 2013
- Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of CarfilzomibDrug Metabolism and Disposition, 2013
- Covalent and non-covalent reversible proteasome inhibitionBiological Chemistry, 2012
- Bortezomib attenuates murine collagen-induced arthritisAnnals of the Rheumatic Diseases, 2009
- A Multicomponent Coupling Sequence for Direct Access to Substituted QuinolinesOrganic Letters, 2009
- The potential of proteasome inhibitors in cancer therapyExpert Opinion on Investigational Drugs, 2008
- Proteasome inhibitor, bortezomib, for myeloma and lymphomaInternational Journal of Clinical Oncology, 2007
- Molecular and Clinical Aspects of Proteasome Inhibition in the Treatment of Cancer2007